Well that was when they were still hoping for PFS and before adding Germany and making a change there to include low absolute lymphocyte count patients. This being an adaptive trial allowed them to learn along the way and make adjustments while still blinded. This is what allowed them to keep going and be accepted by JAMA Oncology. Kind of a big deal!; ). Don’t forget about that BIG TELL from those 17 missing SOC/placebo patients from Germany ; ). Best wishes.
Market Data 
Markets 
AI
